A Type B meeting between the FDA and Plus Therapeutics offered clarity and direction for the next steps in development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback